Search results for "polypeptide"

showing 10 items of 51 documents

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats

2019

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are hormones secreted from the enteroendocrine cells after a meal. They exert their actions through activation of G protein-coupled receptors (R), the GIPR and GLP-2R, respectively. Both have been reported to influence metabolism. The purpose of the study was to investigate the role of the hormones in the regulation of lipid and bone homeostasis by subchronic treatment with novel GIPR and GLP-2R antagonists. Rats were injected once daily with vehicle, GIPR, or GLP-2R antagonists for 3 weeks. Body weight, food intake, body composition, plasma lipoprotein lipase (LPL), adipokines, triglycerides and the mark…

0301 basic medicineAgonistmedicine.medical_specialtyendocrine systemmedicine.drug_classEndocrinology Diabetes and MetabolismAdipokine030209 endocrinology & metabolismSettore BIO/09 - Fisiologialcsh:Diseases of the endocrine glands. Clinical endocrinologyBone resorption03 medical and health sciencesEndocrinology0302 clinical medicineInternal medicinemedicineglucagon-like peptide-2 (GLP-2)ReceptorOriginal Researchlcsh:RC648-665ChemistryLeptindigestive oral and skin physiologyAntagonistGIP receptorGIP receptor antagonistReceptor antagonistlipid homeostasis030104 developmental biologyEndocrinologyglucose-dependent insulinotropic polypeptide (GIP)hormones hormone substitutes and hormone antagonistsHormoneFrontiers in Endocrinology
researchProduct

Pleomorphic Adenoma and Adenoid-Cystic Carcinoma of the Salivary Glands: Comparative Immunohistochemical Patterns

1987

A series of 20 cases of pleomorphic adenoma and 19 cases of adenoid-cystic carcinoma of the salivary glands, and one case in the mammary location, were investigated regarding immunohistochemical reactivity for Tissue Polypeptid Antigen (TPA), Pre-Keratins, Vimentin, S-100 Protein, and their arrangement pattern of fibronectin. As a whole, the results support the hypothesis of morpho-structural and mainly, onto-histogenetic similarities between these tumours, but they also underline the need for great care in outlining their morpho-functional features, in relation to their different prognoses.

0301 basic medicineCancer ResearchPathologymedicine.medical_specialtyAdenoid cystic carcinomaTissue Polypeptide AntigenClinical BiochemistryAdenoma PleomorphicVimentinProtein SPathology and Forensic MedicinePleomorphic adenoma03 medical and health sciences0302 clinical medicineCarcinomaHumansVimentinMedicineTissue Polypeptide AntigenProtein PrecursorsGlycoproteinsbiologybusiness.industryProteinsmedicine.diseaseCarcinoma Adenoid CysticImmunohistochemistryFibronectinsParotid NeoplasmsFibronectin030104 developmental biologyOncology030220 oncology & carcinogenesisbiology.proteinKeratinsImmunohistochemistryPeptidesbusinessThe International Journal of Biological Markers
researchProduct

PACAP38 and PAC1 receptor blockade: a new target for headache?

2018

Abstract Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has not been fully elucidated. Migraine is a neurovascular disorder, recognized as the second most disabling disease. Nevertheless, the antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are the only prophylactic treatment developed specifically for migraine. These antibodies have displayed positive results in clinical trials, but are not effective for all patients; therefore, new pharmacol…

0301 basic medicineSide effectPAC1 receptorMigraine DisordersMigraine Disorders/drug therapylcsh:MedicinePituitary Adenylate Cyclase-Activating Polypeptide/antagonists & inhibitorsReview ArticleTriptansPharmacologyCalcitonin gene-related peptidePACAPNeuroprotectionmigraine; PAC1 receptor; PACAP; prophylactic treatment; animals; disease models animal; headache; humans; migraine disorders; pituitary adenylate cyclase-activating polypeptide; receptors pituitary adenylate cyclase-activating polypeptide type I; neurology (clinical); anesthesiology and pain medicine03 medical and health sciences0302 clinical medicineAnimalsHumansMedicineMigraine treatmentReceptorMigraineHeadache/drug therapybusiness.industrylcsh:RHeadacheGeneral Medicinemedicine.disease3. Good healthBlockadeDisease Models Animal030104 developmental biologyAnesthesiology and Pain MedicineMigrainePituitary Adenylate Cyclase-Activating PolypeptideNeurology (clinical)businessProphylactic treatment030217 neurology & neurosurgeryReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type IReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type I/antagonists & inhibitorsmedicine.drugJournal of Headache and Pain
researchProduct

Radiolabeling of a polypeptide polymer for intratumoral delivery of alpha-particle emitter, 225Ac, and beta-particle emitter, 177Lu

2021

Introduction: Radiotherapy of cancer requires both alpha- and beta-particle emitting radionuclides, as these radionuclide types are efficient at destroying different types of tumors. Both classes of radionuclides require a vehicle, such as an antibody or a polymer, to be delivered and retained within the tumor. Polyglutamic acid (pGlu) is a polymer that has proven itself effective as a basis of drug-polymer conjugates in the clinic, while its derivatives have been used for pretargeted tumor imaging in a research setup. trans-Cyclooctene (TCO) modified pGlu is suitable for pretargeted imaging or therapy, as well as for intratumoral radionuclide therapy. In all cases, it becomes indirectly ra…

0303 health sciencesCancer ResearchAlpha Particle EmitterPolyglutamic acidRadiochemistrySize-exclusion chromatographyPolypeptidesPolyethylene glycolTargeted radionuclide therapyAc030218 nuclear medicine & medical imagingTetrazine ligation03 medical and health scienceschemistry.chemical_compoundTetrazine0302 clinical medicineIon bindingchemistryRadionuclide therapyClick chemistryLuMolecular MedicineDOTARadiology Nuclear Medicine and imaging030304 developmental biology
researchProduct

Effect of gut-derived acetate on glucose turnover in man

1988

1. The effect of acetate absorbed from the gut on glucose turnover has been determined in four healthy subjects during both fasting and an intravenous glucose infusion by using [U-13C]glucose. 2. In the first part of the study, after an overnight fast, a tracer dose of [U-13C]glucose was infused at a constant rate along with an infusion of saline for 7 h. In the second part the saline infusion was replaced by glucose at 4.25 mg min−1 kg−1. In both studies 15 mmol of sodium acetate was given by mouth at 15 min intervals from the fourth to the sixth hour. Glucose turnover, respiratory quotient, metabolic rate and blood levels of acetate, 3-hydroxybutyrate, lactate, insulin, glucagon and gastr…

AdultDietary FiberGlycerolMalemedicine.medical_specialtymedicine.medical_treatmentHydroxybutyratesGastric Inhibitory PolypeptideAcetatesFatty Acids NonesterifiedCarbohydrate metabolismGlucagonAcetic acidchemistry.chemical_compoundGastric inhibitory polypeptideLipid oxidationInternal medicinemedicineHumansInsulinCarbon RadioisotopesAcetic Acid3-Hydroxybutyric AcidChemistryRespirationInsulinGeneral MedicineMetabolismCarbon DioxideGlucagonRespiratory quotientGlucoseEndocrinologyLactatesFemaleClinical Science
researchProduct

Effect of gut-derived acetate on oral glucose tolerance in man.

1988

1. Dietary fibre has a moderating impact on glucose metabolism. To test the hypothesis that this effect of fibre may be mediated by its breakdown product acetate, oral glucose tolerance tests were carried out in healthy volunteers with and without acetate. 2. Five subjects received 50 g of glucose orally while taking either acetate (15 mmol every 15 min) by mouth or chloride as control. Oral acetate made no detectable difference to glucose tolerance or to levels of free fatty acids, 3-hydroxybutyrate, lactate, insulin, glucagon and gastric inhibitory polypeptide. 3. The 50 g dose of glucose temporarily depressed acetate levels in blood. This was probably due to an interaction between glucos…

AdultDietary FiberMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentLumen (anatomy)HydroxybutyratesGastric Inhibitory PolypeptideXyloseCarbohydrate metabolismAcetatesFatty Acids NonesterifiedGlucagonchemistry.chemical_compoundGastric inhibitory polypeptideInternal medicinemedicine3-Hydroxybutyric AcidHumansInsulinGlucose tolerance testmedicine.diagnostic_test3-Hydroxybutyric AcidInsulinGeneral MedicineGlucose Tolerance TestGlucagonEndocrinologyGlucosechemistryLactatesFemaleClinical science (London, England : 1979)
researchProduct

Absence of cardiovascular autonomic dysfunction and vagal pancreatic impairment in idiopathic achalasia of the oesophagus

2007

Abstract  Extra-oesophageal autonomic dysfunction in idiopathic achalasia is not well documented, due to contradictory results reported. We aimed to study the cardiovascular and pancreatic autonomic function in patients with idiopathic achalasia. Thirty patients with idiopathic achalasia (16M/14F; 34.5 ± 10.8 years) and 30 healthy volunteers (13M/17F; 34.8 ± 10.7 years) were prospectively studied. Age >60 years and conditions affecting results of autonomic evaluation were excluded. Both groups underwent the sham feeding test and plasmatic levels of pancreatic polypeptide (PP) were determined by radioimmunoassay (basal, at 5, 10, 20 and 30 min). Cardiovascular parasympathetic (deep breathing…

AdultMaleAutonomic functionmedicine.medical_specialtyAdolescentPhysiologyDiaphragmatic breathingAchalasiaAutonomic Nervous SystemPancreatic PolypeptideEatingEsophagusInternal medicinemedicineHumansPancreatic polypeptideEndocrine and Autonomic Systemsbusiness.industryGastroenterologyVagus NerveRadioimmunoassayMiddle Agedmedicine.diseaseSham feedingEsophageal AchalasiaBlood pressureTasteAnesthesiaCardiologyMasticationFemaleIdiopathic achalasiabusinessNeurogastroenterology & Motility
researchProduct

Autonomic dysfunction in patients with achalasia.

1995

It has been previously shown that patients with achalasia may have motor abnormalities of the stomach, small bowel and biliary system. This study investigates whether a disturbance of extraintestinal autonomic function occurs. Autonomic function studies were performed in 15 patients with achalasia and 15 age- and sex-matched healthy controls. Pupillo-grams were obtained during darkness, light exposure and after pilocarpine administration. Cardiovascular function studies included determinations of heart rate variation during deep breathing and orthostasis. In addition, we determined blood pressure changes in response to sustained handgrip, cold exposure and orthostasis. Neurohormonal functio…

AdultMalemedicine.medical_specialtyPhysiologyAchalasiaDiaphragmatic breathingAutonomic Nervous SystemPancreatic PolypeptideInternal medicineReflexmedicinePancreatic polypeptideHumansEndocrine and Autonomic Systemsbusiness.industryStomachNeuropeptidesGastroenterologyHemodynamicsPupilMiddle Agedmedicine.diseaseSham feedingEsophageal AchalasiaAutonomic nervous systemmedicine.anatomical_structureBlood pressurePilocarpineAnesthesiaCardiologyFemalebusinessmedicine.drugNeurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
researchProduct

PACAP induces bradycardia in guinea-pig heart by stimulation of atrial cholinergic neurones

1996

Based on previous studies which indicated that pituitary adenylate cyclase activating peptide (PACAP) acts as a positive inotropic and chronotropic substance in different species via the cAMP signal transduction pathway, the objective of the present work was to investigate cAMP-regulated myocardial key proteins in response to PACAP in isolated ventricular cells of the guinea pig. Surprisingly, the two molecular forms of PACAP, PACAP(1-27) and PACAP(1-38), showed no effect on intracellular cAMP-levels, L-type Ca2+ channel current or phosphorylation of troponin inhibitor (TnI) and phospholamban (PLB). Additionally, inotropy of isolated guinea-pig ventricular strips was not affected by the neu…

AtropineMaleChronotropicendocrine systemmedicine.medical_specialtyGuinea PigsReceptors Pituitary Adenylate Cyclase-Activating PolypeptideStimulationIn Vitro TechniquesBiologyInternal medicineBradycardiaCyclic AMPmedicineAnimalsHeart AtriaReceptors Pituitary HormonePatch clampNeuronsPharmacologyNeurotransmitter AgentsMyocardiumCalcium-Binding ProteinsNeuropeptidesGeneral MedicineAcetylcholineRatsPhospholambanElectrophysiologyAtropinePituitary adenylate cyclase-activating peptideEndocrinologycardiovascular systemPituitary Adenylate Cyclase-Activating PolypeptideCholinergicFemalehormones hormone substitutes and hormone antagonistsAcetylcholineReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type ISignal Transductionmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Incretins, Pregnancy, and Gestational Diabetes

2015

The number of pregnant women affected by gestational diabetes mellitus (GDM) is increasing among Caucasians, and East Asians. GDM also increases the risk for later advent of type 2 diabetes mellitus (T2DM), obesity, and cardiovascular disease in both women and their offspring. The underlying mechanism of GDM is not fully elucidated. Incretins such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), have been suggested to have a role in maternal metabolism and weight as well as fetal growth. These hormones might be implicated in mechanisms that compensate for the increment in glycemia and insulin resistance seen during pregnancy, while other factors, such a…

Blood Glucose0301 basic medicineendocrine systemmedicine.medical_specialtyendocrine system diseasesOffspringPharmaceutical ScienceIncretinGastric Inhibitory PolypeptideType 2 diabetes030204 cardiovascular system & hematologyIncretins03 medical and health sciences0302 clinical medicineInsulin resistanceGlucagon-Like Peptide 1PregnancyRisk FactorsInternal medicineGlucose IntoleranceAnimalsHumansMedicineObesityPregnancybusiness.industrynutritional and metabolic diseasesType 2 Diabetes MellitusType 2 diabetesIncretinmedicine.diseaseObesityGestational diabetesDiabetes Gestational030104 developmental biologyEndocrinologyGestational diabeteDiabetes Mellitus Type 2FemaleInsulin Resistancebusinesshormones hormone substitutes and hormone antagonistsBiotechnologyCurrent Pharmaceutical Biotechnology
researchProduct